{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:30:54Z","timestamp":1787772654868,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>In Asians, polypoidal choroidal vasculopathy (PCV) is becoming more widely recognized as a significant cause of exudative maculopathy. The previous set of Indian guidelines on the management of PCV were published in 2018, with a literature search updated up to November 2015. As the treatment of PCV evolves, retinal physicians must constantly modify their current practice. The current guidelines are based on the most up-to-date information on PCV and are an update to the previous set of guidelines. These guidelines were developed by a panel of Indian retinal experts under the aegis of the Vitreoretinal Society of India (VRSI), based on a comprehensive search and assessment of literature up to September 2021. The final guidelines i) provide the updated nomenclature in PCV; ii) discusses the newer diagnostic imaging features of PCV, especially in the absence of indocyanine green angiography (ICGA); and iii) recommends the best possible therapeutic approach in the management of PCV, including the choice of anti-vascular endothelial growth factor (anti-VEGF) agents, treatment regimen, and the role of switching between the anti-VEGF agents. In the face of non-availability of photodynamic therapy (PDT) in India, we constructed practical recommendations on anti-VEGF monotherapy in PCV. The current updated recommendations would provide a broader framework to the treating retinal physician for the diagnosis and management of PCV for optimal therapeutic outcomes.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2985_21","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T11:45:11Z","timestamp":1659613511000},"page":"3102-3111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Updated guidelines for the management of polypoidal choroidal vasculopathy: Recommendations from the Indian Polypoidal Choroidal Vasculopathy Panel and the Vitreoretinal Society of India"],"prefix":"10.4103","volume":"70","author":[{"given":"Jay U","family":"Sheth","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Chaithanya Eye Hospital, Trivandrum, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Vitreoretinal Society of India (VRSI) General Secretary, Vitreoretinal Society of India, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar","family":"Anantharaman","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, Giridhar Eye Institute, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Bhende","sequence":"additional","affiliation":[{"name":"Department of Vitreoretinal Services, Sri Bhagwan Mahavir Vitreoretinal Services, Medical Research Foundation, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Chawla","sequence":"additional","affiliation":[{"name":"Vitreoretinal Society of India (VRSI) President, Vitreoretinal Society of India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Vitreoretinal Society of India (VRSI) Convenor Scientific Committee, Vitreoretinal Society of India, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","article-title":"Polypoidal choroidal vasculopathy:Pearls in diagnosis and management","volume":"66","author":"Anantharaman","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy:Consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.oret.2021.04.002","article-title":"Non-ICGA treatment criteria for suboptimal anti-VEGF response for polypoidal choroidal vasculopathy:APOIS PCV workgroup report 2","volume":"5","author":"Chong","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy:Two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","article-title":"Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy","volume":"27","author":"Hirami","year":"2007","journal-title":"Retina"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archopht.123.10.1347","article-title":"Complications after photodynamic therapy","volume":"123","author":"Schnurrbusch","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4103\/ijo.IJO_174_17","article-title":"Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects","volume":"65","author":"Rishi","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","article-title":"Photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Nowak-Sliwinska","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1167\/iovs.02-0604","article-title":"Sequence of early vascular events after photodynamic therapy","volume":"44","author":"Michels","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B11-20240828","first-page":"830","article-title":"Photodynamic effects on choroidal neovascularization and physiological choroid","volume":"43","author":"Schmidt-Erfurth","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3928\/15428877-20090430-14","article-title":"Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy","volume":"40","author":"Kim","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ajo.2009.09.020","article-title":"One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy","volume":"149","author":"Yamashita","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy:96-week outcomes in the Japanese subgroup of the PLANET study","volume":"65","author":"Ogura","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"EVEREST II study group. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy:The EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"LAPTOP study:A 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","volume":"121","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy:The Fujisan Study","volume":"35","author":"Gomi","year":"2015","journal-title":"Retina"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","article-title":"Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy","volume":"165","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"B19-20240828","first-page":"35","article-title":"Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection Jpn J Ophthalmol","volume":"60","author":"Saito","year":"2016"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","article-title":"Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab","volume":"34","author":"Saito","year":"2014","journal-title":"Retina"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2147\/OPTH.S50634","article-title":"Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis","volume":"7","author":"Miura","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4103\/ijo.IJO_1003_16","article-title":"Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes:Early experience","volume":"65","author":"Bansal","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41598-018-37523-5","article-title":"Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40123-020-00312-3","article-title":"One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"9","author":"Tamachi","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.2147\/OPTH.S328160","article-title":"Brolucizumab in neovascular age-related macular degeneration - Indian Real-World Experience:The Braille study","volume":"15","author":"Chakraborty","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","article-title":"Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","article-title":"Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy:Retrospective study and systematic review","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend Regimen:FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1177\/11206721211014717","article-title":"One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy","volume":"31","author":"Rouvas","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"B30-20240828","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","article-title":"Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy","volume":"106","author":"Teo","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"OCT526","DOI":"10.1167\/iovs.15-18955","article-title":"Evaluating polypoidal choroidal vasculopathy with optical coherence tomography angiography","volume":"57","author":"Wang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajo.2020.05.017","article-title":"A comparison study of polypoidal choroidal vasculopathy imaged with indocyanine green angiography and swept-source optical coherence tomography angiography","volume":"217","author":"Kim","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0000000000001702","article-title":"Polypoidal choroidal vasculopathy upon optical coherence tomographic angiography","volume":"38","author":"Chan","year":"2018","journal-title":"Retina"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1097\/IAE.0000000000000777","article-title":"Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization","volume":"35","author":"Inoue","year":"2015","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2985_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:07:41Z","timestamp":1787771261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2985_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2985_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"2021-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}